264 related articles for article (PubMed ID: 30714086)
1. Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations.
Howell M; Walker RC; Howard K
Appl Health Econ Health Policy; 2019 Jun; 17(3):315-330. PubMed ID: 30714086
[TBL] [Abstract][Full Text] [Related]
2. The Cost-Effectiveness of Kidney Replacement Therapy Modalities: A Systematic Review of Full Economic Evaluations.
Yang F; Liao M; Wang P; Yang Z; Liu Y
Appl Health Econ Health Policy; 2021 Mar; 19(2):163-180. PubMed ID: 33047212
[TBL] [Abstract][Full Text] [Related]
3. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of contemporary home haemodialysis modalities compared with facility haemodialysis: a systematic review of full economic evaluations.
Walker R; Marshall MR; Morton RL; McFarlane P; Howard K
Nephrology (Carlton); 2014 Aug; 19(8):459-70. PubMed ID: 24750559
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
6. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.
Wong CKH; Chen J; Fung SKS; Mok MMY; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
Nephrol Dial Transplant; 2019 Sep; 34(9):1565-1576. PubMed ID: 30668781
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
Yang F; Lau T; Luo N
Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway.
Busink E; Kendzia D; Kircelli F; Boeger S; Petrovic J; Smethurst H; Mitchell S; Apel C
Eur J Health Econ; 2023 Apr; 24(3):377-392. PubMed ID: 35716316
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
[TBL] [Abstract][Full Text] [Related]
10. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.
De Vecchi AF; Dratwa M; Wiedemann ME
Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710
[TBL] [Abstract][Full Text] [Related]
11. The Cost Effectiveness of High-Dose versus Conventional Haemodialysis: a Systematic Review.
Laplante S; Liu FX; Culleton B; Bernardo A; King D; Hudson P
Appl Health Econ Health Policy; 2016 Apr; 14(2):185-93. PubMed ID: 26691659
[TBL] [Abstract][Full Text] [Related]
12. Health economic evaluations: the special case of end-stage renal disease treatment.
Winkelmayer WC; Weinstein MC; Mittleman MA; Glynn RJ; Pliskin JS
Med Decis Making; 2002; 22(5):417-30. PubMed ID: 12365484
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of dialysis therapies.
Klarenbach S; Manns B
Semin Nephrol; 2009 Sep; 29(5):524-32. PubMed ID: 19751898
[TBL] [Abstract][Full Text] [Related]
14. Cost of Dialysis Therapy by Modality in Manitoba.
Beaudry A; Ferguson TW; Rigatto C; Tangri N; Dumanski S; Komenda P
Clin J Am Soc Nephrol; 2018 Aug; 13(8):1197-1203. PubMed ID: 30021819
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
16. Financial implications of dialysis modalities in the developing world: A Chinese perspective.
Liu J; Hutton DW; Gu Y; Hu Y; Li Y; Ma L; Zeng X; Fu P
Perit Dial Int; 2020 Mar; 40(2):193-201. PubMed ID: 32063196
[TBL] [Abstract][Full Text] [Related]
17. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
18. Healthcare costs of patients on different renal replacement modalities - Analysis of Dutch health insurance claims data.
Mohnen SM; van Oosten MJM; Los J; Leegte MJH; Jager KJ; Hemmelder MH; Logtenberg SJJ; Stel VS; Hakkaart-van Roijen L; de Wit GA
PLoS One; 2019; 14(8):e0220800. PubMed ID: 31415578
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia.
Hooi LS; Lim TO; Goh A; Wong HS; Tan CC; Ahmad G; Morad Z
Nephrology (Carlton); 2005 Feb; 10(1):25-32. PubMed ID: 15705178
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
